title: Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.
abstract: The spectrum of CD30+ cutaneous lymphoproliferative disorders is characterized by the histology of a high-grade lymphoma but frequent clinical regression of skin lesions in lymphomatoid papulosis (LyP) and occasional regression in CD30+ large cell lymphomas (LCLs). A recent study shows that apoptosis may be a significant mechanism of regression of LyP (Arch Dermatol 133:828-833, 1997). Therefore, we studied expression of proteins that induce apoptosis, including CD27, CD40, CD95, and nerve growth factor receptor (NGF-R), as well as anti-apoptotic protein bcl-2 in skin lesions from 25 patients within the spectrum of CD30+ cutaneous lymphoma. Our results show consistent expression of CD95 (APO-1/Fas), but rare or absent expression of CD27, CD40, and NGF-R on tumor cells from both regressing LyP lesions and nonregressing CD30+ lymphomas. Bcl-2 was expressed at low levels in LyP and at high levels in pleomorphic CD30+ lymphomas. These results indicate that, in addition to CD30, CD95 expression is preferentially expressed at high levels in all cutaneous CD30+ lymphomas and suggest that CD95 may play a role in the regression of CD30+ skin lesions. Expression of bcl-2 appears to protect tumor cells from apoptosis in CD30+ lymphoproliferative disorders.
authors.affiliation: Research Unit/Anatomic Pathology and Dermatology I.R.C.C.S. Policlinico S. Matteo and University of Pavia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Paulli
authors.forename: E
authors.initials: E
authors.lastname: Berti
authors.forename: E
authors.initials: E
authors.lastname: Boveri
authors.forename: S
authors.initials: S
authors.lastname: Kindl
authors.forename: E
authors.initials: E
authors.lastname: Bonoldi
authors.forename: C
authors.initials: C
authors.lastname: Gambini
authors.forename: R
authors.initials: R
authors.lastname: Rosso
authors.forename: G
authors.initials: G
authors.lastname: Borroni
authors.forename: V
authors.initials: V
authors.lastname: Straccapansa
authors.forename: U
authors.initials: U
authors.lastname: Magrini
authors.forename: J E
authors.initials: JE
authors.lastname: DeCoteau
authors.forename: P H
authors.initials: PH
authors.lastname: Krammer
authors.forename: P
authors.initials: P
authors.lastname: Möller
authors.forename: M E
authors.initials: ME
authors.lastname: Kadin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000096:biosynthesis*; D008223:Lymphoma / Q000378:metabolism* / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis*; D017475:Receptors, Nerve Growth Factor / Q000096:biosynthesis; D018124:Receptors, Tumor Necrosis Factor / Q000096:biosynthesis; D012871:Skin Diseases / Q000378:metabolism / Q000473:pathology; D012878:Skin Neoplasms / Q000378:metabolism* / Q000473:pathology; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000096:biosynthesis; D019014:fas Receptor / Q000096:biosynthesis*
chemical_list: D017730:Ki-1 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D017475:Receptors, Nerve Growth Factor; D018124:Receptors, Tumor Necrosis Factor; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D019014:fas Receptor